

# Sneak Peek

*Process Scale-up, Validation  
and Technology Transfer for Biologics*

---



**Dr. Sam Denby**

Managing Partner, BioFrey,  
United Kingdom



**ONLINE  
TRAINING**




**SYMMETRIC**

# General Principles

01


The FDA Guidance Process Validation: General Principles and Practices (2011) identifies three stages to process validation



**Broadly speaking, this is the model most companies follow**

# Continually de-risking process

02



PC Study Design to support confirmation of cPP

Alt et al Biologicals Volume 44, Issue 5, September 2016, Pages 291-305  
<https://doi.org/10.1016/j.biologicals.2016.06.005>

A note on QbD. The above is generally accepted to be QbD. By following these principles you continually increase the likelihood of producing a product of acceptable quality. QbD CAN deliver a design space, but has done so very infrequently (1 filing)

# Selecting a manufacturing site

03

## Long term relationship

Consider pre-existing relationships – do you have an internal manufacturing site?

Are there CMO's you have worked with previously?

Is development capability critical?

Location?

Prior experience of site?

Audit history/site licenses?

Contract terms



## How?

RFP – Ideally involve a procurement professional/consultant. CMC, SME and quality oversight/input

Kepnor Tregoe Matrix

# Selecting a manufacturing site



## What is a Critical Quality attribute (CQA)

### 3.2.4.2 Critical Quality Attribute (CQA)

A Critical Quality Attribute (CQA), according to ICH Q8(R2), is “a physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality.” To determine a CQA, in principle, is a fairly straightforward three-step process; but, in reality, takes a considerable CMC team resource commitment to carry

## How are CQA's identified

1. List all of the quality attributes (i.e. molecular and functional properties or characteristics) of the biologic
2. Select an ICH Q9 quality risk assessment tool (e.g. RRF or FMEA) and systematically assign a risk score to each and every listed quality attribute
3. Decide what risk score value will be identified as critical

# Obligatory CQA's

05

## DS and DP

Composition and strength (for a Mab)

- Protein content
- Osmolality
- pH
- Appearance (color, opalescence, clarity)
- Buffer Content
- Excipient Content
- Surfactant Content

Adventitious agent control

- Viruses
- Screening of raw mats esp. cell banks,
- Viral clearance
- Testing of clarified harvest
- Microbiological impurities (Bacteria, Mycoplasma)
- Bacterial Endotoxins

## DP Specific

- Subvisible particles
- Visible particles
- Extractbale volume
- Sterility

# Validation Master Plan



Validation master plan brings all of the work that has been done to date together it's an opportunity to tell the story of the molecule, facility and process. Going forward it's an important document to support key activities such as regulatory filings and inspections. It should be molecule specific.

Many sites (including CDMOs) will have personnel who are highly skilled in designing and executing these protocols. Whoever you are working with, leveraging their expertise is crucial.

Validation master plans typically include:

- Introduction
- Purpose
- Roles and responsibilities
- Overall approach to validation
- Process description
- Process design (History, development, characterization)
- Manufacturing process control strategy
- Process qualification
  - Facility
  - PPQ strategy
  - PPQ Pre-requisites
  - Campaign
  - Specifications and testing
- Supplemental Studies
- Continued process verification

# Registration

## Sneak Peek

*Process Scale-up, Validation and Technology Transfer for Biologics*

07




---

Mliekarenská 9, 821 09  
Bratislava, Slovak Republic  
ID: 47 068 124  
VAT no: SK2023741973  
Office: +421 948 262 346

🛡 100% Secure payments

Your details are protected and safe with us. Taxes calculated at the checkout.





SYMMETRIC

# Your Partner for Pharma, Biotech and Medical Device Training

We train clients from over 500 companies annually. Enter our global educational platform for pharmaceutical professionals.

[VIEW ALL TRAINING COURSES](#)